INAUGURAL POST
Nonpartisan pharma news and views from the horse’s mouth, not the jockey’s
WE NEED TO KNOW THIS WILL GET PROPER REGULATORY SCRUTINY
Hot on the heels of the Pfizer/BioNTech SARS-CoV-2 injection comes the next candidates for mRNA treatment – Shingles.
In an article published in PHARMACEUTICAL TECHNOLOGY, titled Pfizer and BioNTech enter deal to develop first mRNA vaccine for shingles, January 6, 2022, the deal was described by Pfizer Worldwide Research, Development & Medical chief scientific officer and president Mikael Dolsten as so: “With this agreement, we continue on our journey of discovery together, by advancing mRNA technology to tackle another health challenge ripe for scientific innovation, supported by our world-class manufacturing network.”
Inside Pharma says:
Given there is no rationale for an emergency approval, this MUST go through the normal channels before being approved for use in humans.
Regulations (laws) on licensing new drugs have been harmonised globally in recent years under the auspices of The International Council for Harmonisation of Tech…